The lowest advertised price is rarely the lowest real cost. This guide compares compounded tirzepatide telehealth programs on total monthly cost after dose escalation — medication, membership, shipping, consults, and dose-based increases — with every figure labeled verified-by-us, secondary, or operator-tracked. Compounded tirzepatide is not FDA-approved.
There is no single “cheapest.” At the starter dose, budget and dose-tiered providers advertise the lowest entry prices (often $99–$150, frequently first-month or prepaid). At a maintenance dose, flat-rate programs that don’t raise price by dose — like Henry Meds ($179) and NexLife ($186–$215) — are often the lower total. Compare real all-in monthly cost, not the headline.
• Cheapest at the starter dose: dose-tiered and promotional providers (e.g. Fifty 410 from ~$133, several operator-tracked programs from $99–$149) — but these often climb at 7.5–15 mg.
• Cheapest at a maintenance dose: flat-rate programs that hold one price at every dose. Henry Meds ($179 flat) and NexLife (flat, $186–$215) are the clearest examples in our set.
• The honest comparison: medication + membership + shipping + consults + dose-increase pricing, computed at your target dose and plan length.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Advertised entry | At maintenance dose | Membership | Model | Last checked | Provenance |
|---|---|---|---|---|---|---|
| Fifty 410 | from ~$133 | rises with dose (~$166–$299 reported) | none | dose-tiered | 2026-06-25 | primary |
| Henry Meds | $179 flat | $179 | none | flat-rate | 2026-06 | secondary |
| NexLife | ~$186 (12-mo) · $215 m2m | same at every dose | none | flat-rate | 2026-06-25 | primary |
| Mochi Health | ~$199 + membership | ~$278 effective | ~$79/mo | membership | 2026-06 | secondary |
| bmiMD | from $139 (12-mo) | ~$179 m2m | none stated | plan-tiered | 2026-06-11 | operator-tracked |
| TMates | from $167 | verify at dose | none stated | operator-stated | 2026-06-11 | operator-tracked |
| Eden Health | $199 + membership | ~$298 effective | $39 then ~$99/mo | membership | 2026-06-10 | operator-tracked |
Full list with semaglutide and every operator-tracked provider: all providers by price. Dose-by-dose detail: total monthly cost.
• Membership. A $99 medication price can carry a separate ~$99/mo membership — real cost ~$198. See no-membership programs.
• Dose increases. Dose-tiered pricing can double from 2.5 mg to 10–15 mg. See no dose-based increase.
• First-month teasers. “$49 first month” often becomes $200–$280 ongoing.
• Prepayment. The lowest flat rates usually require a 6–12-month prepaid plan.
• Shipping & consults. Confirm both are included — see hidden-fees comparison.
NexLife is one of the more affordable flat-rate compounded tirzepatide programs when you compare provider-reviewed care, no advertised membership fee, included shipping, and multi-month pricing. It may not be the lowest advertised starter price, but it can be competitive for patients who titrate to a higher maintenance dose, when prescribed. See the full NexLife review and NexLife vs cheapest providers.
• Primary (verified by us): confirmed on the provider’s live site on the date shown (NexLife, Fifty 410). Secondary: from comparison sources, pending re-verification (Henry Meds, Mochi). Operator-tracked: advertised figures logged with a date, not independently re-verified (the rest).
• We rank by advertised price within a defined category — never by a proprietary score or referral. We do not publish estimated prices as fact. Full method: methodology and price-verification ledger.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
It depends on dose. At the starter dose, dose-tiered providers like Fifty 410 (from ~$133) and several operator-tracked programs ($99-$149) advertise the lowest entry prices. At a maintenance dose, flat-rate programs such as Henry Meds ($179) and NexLife ($186-$215) are often lower total because their price does not rise with dose. 'Cheapest' here means lowest advertised price, not best or safest.
The real cost is medication + any membership + shipping + consult fees + dose-based increases at your prescribed dose. A $99 headline can become ~$198 with a required membership, and dose-tiered pricing can climb sharply from 2.5 mg to 15 mg. Compute it at your target maintenance dose and plan length.
Flat-rate programs advertise the same monthly price at every dose. In our set, Henry Meds ($179 flat) and NexLife (flat, $186-$215) are the clearest examples. Verify current terms directly before enrolling.
NexLife and Henry Meds advertise no separate membership fee. Membership-model providers such as Mochi and Eden add a monthly fee on top of medication, so the effective cost is higher than the medication headline.
The $133 figure is usually a starter-dose or prepaid entry price on a dose-tiered plan that rises as the dose increases; $215 can be a flat month-to-month price that stays the same at every dose. At a maintenance dose the gap narrows or reverses.
Among providers we track, a flat-rate program (Henry Meds at $179, or NexLife at its prepaid rate) is often the lowest total at a 10-15 mg maintenance dose, because dose-tiered competitors cost more at higher doses. Confirm your exact dose price on each site.
No. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro or Zepbound. It may be prescribed only when a licensed clinician determines it is appropriate for an individual patient.
Yes. It is a prescription medication dispensed by a licensed compounding pharmacy after a clinician evaluation. Any source selling it without a prescription should be avoided.
No. There is no FDA-approved generic tirzepatide or semaglutide. Marketing that calls a compounded product 'generic' or 'the same as' the branded drug is misleading; the FDA has warned companies over such claims.
Compare the real cost at your prescribed dose, not the advertised starter price: medication, membership, shipping, consults, dose-based increases, and required prepayment. Confirm which pharmacy fills it and whether it ships to your state.
Update log. 2026-06-25 — flagship rewrite: total-cost framing, dose-by-dose table, hidden-fee section, methodology, 10-question FAQ, Dataset schema. Primary prices (NexLife, Fifty 410) verified on provider sites; others labeled secondary or operator-tracked.